iBio to Begin Trading on the Nasdaq Stock Exchange

Core Points - iBio, Inc. has received approval to transfer its common stock listing from NYSE American to the Nasdaq Capital Market, with trading expected to commence on March 4, 2025, under the symbol "IBIO" [1][2] - The CEO of iBio expressed optimism that the move to Nasdaq will enhance the visibility of the company's stock, improve trading liquidity, and provide greater exposure to institutional investors [2] Company Overview - iBio, Inc. is a biotech company focused on developing next-generation biopharmaceuticals for various diseases, including cardiometabolic diseases, obesity, and cancer, utilizing AI and advanced computational biology [2] - The company aims to transform drug discovery and accelerate development timelines through proprietary 3D modeling and innovative drug discovery platforms, creating a pipeline of breakthrough antibody treatments [2]